Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward
Takeda and Lundbeck-partnered rare neurological disorder company Ovid Therapeutics has some encouraging mid-stage data from a Fragile X study testing its lead drug, but there remain questions about the optimal dose to take forward into a pivotal trial.
Three regimens of the drug, OV101, (5 mg once-daily, twice-daily and thrice-daily) were randomized in 23 male patients with a confirmed diagnosis of Fragile X syndrome (FXS), the most common inherited form of intellectual disability and autism and is caused by a mutation in the FMR1 gene. The condition has no approved therapies so far.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
